In recent trading, Regeneron Pharmaceuticals, Inc. (REGN) shares reached $820.00, surpassing the average analyst 12-month target price of $816.30. This shift invites analysts to either adjust their valuations or reassess their target prices based on current market conditions.
A total of 20 analysts contribute to the average price target, with predictions ranging from a low of $605.00 to a high of $970.00, and a standard deviation of $87.33. Currently, 15 analysts rated the stock as a strong buy, while 6 hold and 1 sell, indicating a favorable outlook among investors. The average rating has improved from 1.93 three months ago to 1.68 now, suggesting growing confidence in Regeneron’s performance.
